Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Convertible Debt (2017 - 2020)

Neuroone Medical Technologies filings provide 2 years of Convertible Debt readings, the most recent being $1.0 million for Q3 2020.

On a quarterly basis, Convertible Debt changed N/A to $1.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $1.0 million, a N/A change, with the full-year FY2020 number at $1.0 million, changed N/A from a year prior.
Convertible Debt hit $1.0 million in Q3 2020 for Neuroone Medical Technologies, down from $2.2 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $2.2 million in Q4 2017 to a low of $1.0 million in Q3 2020.